GLP-1 Receptor Agonists Linked to Fewer Diabetic Foot Ulcers but Higher Charcot Risk Than DPP-4 Inhibitors
核心洞察
A propensity-matched analysis of nearly 40,000 U.S. adults with type 2 diabetes (搜索) and neuropathy found GLP-1 receptor agonist (搜索) users had a 19% lower risk of diabetic foot ulcers at one year versus DPP-4 inhibitor (搜索) users (HR 0.813; 95% CI, 0.716–0.922).
Charcot neuroarthropathy (搜索) occurred at nearly twice the rate in the GLP-1 group (HR 1.993; 95% CI, 1.297–3.064), a rare but statistically significant safety signal.
Rates of lower-extremity amputation and osteomyelitis (搜索) were indistinguishable between groups, while all-cause mortality was lower in the GLP-1 cohort, interpreted as hypothesis-generating.
GLP-1 receptor agonists, the blockbuster class behind medications such as semaglutide and liraglutide, may reshape the fate of one of diabetes' most feared complications: the diabetic foot. A new analysis of nearly 40,000 U.S. adults with type 2 diabetes (搜索) and nerve damage, published in the Journal of Neurology, reports that patients starting a GLP-1 receptor agonist (搜索) developed diabetic foot ulcers at a lower rate than similar patients starting a DPP-4 inhibitor (搜索). However, the study also carries a cautionary note: the GLP-1 group experienced nearly twice the rate of Charcot neuroarthropathy (搜索), a rare and destructive collapse of the bones and joints of the foot.
Led by Fady Tawfik of Howard University College of Medicine (搜索), with colleagues at Texas A&M University College of Medicine and the University of Maryland School of Medicine, the research team analyzed the TriNetX US Collaborative Network, a federated database of de-identified electronic health records. They identified adults with type 2 diabetes (搜索) mellitus and diabetic neuropathy (ICD-10-CM code E11.40) who had newly initiated either a GLP-1 receptor agonist (搜索) or a DPP-4 inhibitor (搜索). Both drug classes act on the incretin system but through different mechanisms: GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone directly, while DPP-4 inhibitors block the enzyme dipeptidyl peptidase-4 that normally degrades endogenous GLP-1.
Study Design and Endpoints
Because patients prescribed these drugs often differ systematically in age, weight, kidney function, and disease burden, the investigators applied 1:1 propensity score matching, pairing each GLP-1 receptor agonist (搜索) user with a DPP-4 inhibitor (搜索) user sharing a similar demographic and clinical profile. After exclusions and matching, the final cohorts contained 19,770 patients per group. The researchers tracked five outcomes over one and two years: diabetic foot ulcer (搜索), lower-extremity amputation, osteomyelitis (搜索) of the foot or ankle, Charcot neuroarthropathy (搜索), and all-cause mortality. Time-to-event analyses employed Kaplan–Meier curves and Cox proportional hazards models, with a Bonferroni correction setting statistical significance at p less than 0.01.
Ulcer Reduction and Mortality Signal
The headline result concerned foot ulcers, the most common entry point into neuropathic foot disease. At one year, 2.2 percent of GLP-1 receptor agonist (搜索) users had been diagnosed with a diabetic foot ulcer (搜索) compared with 2.7 percent of DPP-4 inhibitor (搜索) users, corresponding to a hazard ratio of 0.813 (95% CI, 0.716–0.922) — roughly a 19 percent relative reduction in ulcer risk. All-cause mortality was also lower in the GLP-1 group, a finding the authors interpreted as hypothesis-generating rather than definitive given the observational design and possibility of residual confounding.
A Divergent Safety Signal
Not every result favored the newer drugs. Charcot neuroarthropathy (搜索) occurred in 0.3 percent of GLP-1 users versus 0.2 percent of DPP-4 inhibitor (搜索) users, a hazard ratio of 1.993 (95% CI, 1.297–3.064), meaning nearly a doubling of risk that reached statistical significance. By contrast, rates of lower-extremity amputation (0.5 percent in both groups) and foot or ankle osteomyelitis (搜索) (0.4 percent in both groups) were indistinguishable, with hazard ratios crossing unity comfortably.
Proposed Mechanisms
The authors and prior literature point to several plausible mechanisms for the divergent findings. Charcot neuroarthropathy (搜索) is widely understood as an "imperfect storm": an injury to an insensate foot triggers an exaggerated inflammatory response in which osteoclast-driven bone resorption outpaces repair. Rapid improvements in glycemic control are a recognized trigger for acute neuropathic and Charcot events, related to treatment-induced neuropathy of diabetes. Because GLP-1 receptor agonists are potent glucose-lowering agents, their initiation in patients with poorly controlled diabetes could reproduce this dynamic, destabilizing bone in a foot already numbed by neuropathy.
Counteracting mechanisms may explain the ulcer benefit. Experimental work has shown that GLP-1 receptor signaling exerts neuroprotective and anti-inflammatory effects on peripheral nerves, including damping the p38 MAPK and nuclear factor kappa-B inflammatory pathways. Independent of nerves, GLP-1 signaling appears to accelerate wound repair through the PI3K/Akt pathway and vascular endothelial growth factor signaling.
Clinical Implications and Limitations
As a retrospective cohort study of administrative coding data, the analysis cannot prove causation. Unmeasured confounding remains possible despite propensity matching, including channeling bias in which physicians may preferentially prescribe GLP-1 receptor agonists to healthier or more adherent patients. Coding of Charcot neuroarthropathy (搜索) is uncommon and inconsistently applied, and although the doubling of risk reached the corrected significance threshold, the absolute numbers were small — roughly three additional cases per thousand patients per year. The modest absolute reduction in ulcers, about five additional ulcer-free patients per thousand at one year, likewise requires context.
Even so, the study carries practical messages. For patients with type 2 diabetes (搜索) and established neuropathy, GLP-1 receptor agonist (搜索) therapy appears, on balance, favorable for foot health, reinforcing established cardiovascular and mortality benefits. But clinicians initiating these potent glucose-lowering agents in patients with preexisting nerve damage should remain alert to the rare possibility of rapid glycemic improvement triggering neuropathic worsening or Charcot joint destruction. The authors emphasize that vigilant foot surveillance during therapy, including prompt evaluation of warmth, swelling, or deformity in an insensate foot, is warranted. Charcot neuroarthropathy (搜索) caught early can be treated with offloading and immobilization before irreversible deformity sets in; caught late, it is a leading cause of amputation.